Publications by authors named "Heidi Greulich"

52Publications

Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.

Int J Cancer 2020 04 9;146(8):2194-2200. Epub 2019 Jul 9.

Department of Nanobiomedical Science, Dankook University, Cheonan, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32499DOI Listing
April 2020

Landscape of genomic alterations in cervical carcinomas.

Nature 2014 Feb 25;506(7488):371-5. Epub 2013 Dec 25.

1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA [2] The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA [3] Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA [4].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature12881DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161954PMC
February 2014

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cancer Res 2013 Nov 24;73(22):6770-9. Epub 2013 Sep 24.

Authors' Affiliations: Departments of Medical Oncology and Cancer Biology; Center for Cancer Genome Discovery, Lowe Center for Thoracic Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of Medicine, Brigham and Women's Hospital; Departments of Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, Boston, Massachusetts; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea; and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903789PMC
November 2013

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.

Front Oncol 2013 23;3:86. Epub 2013 Apr 23.

Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA, USA ; Department of Medicine, Harvard Medical School Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632856PMC
May 2013

Targeting mutant fibroblast growth factor receptors in cancer.

Trends Mol Med 2011 May 1;17(5):283-92. Epub 2011 Mar 1.

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2011.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809064PMC
May 2011

Somatic mutations affect key pathways in lung adenocarcinoma.

Nature 2008 Oct;455(7216):1069-75

The Genome Center at Washington University, Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature07423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694412PMC
October 2008

Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.

Mol Cell Biol 2008 Oct 18;28(20):6223-33. Epub 2008 Aug 18.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00658-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577431PMC
October 2008

Probing the cancer genome.

Authors:
Heidi Greulich

Genome Biol 2008 15;9(5):309. Epub 2008 May 15.

Dana-Farber Cancer Institute, Binney St, Boston, MA 02115, and Broad Institute of MIT and Harvard, Cambridge Center, Cambridge, MA 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/gb-2008-9-5-309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441462PMC
July 2008

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.

Nucleic Acids Res 2008 Apr 27;36(7):2446-56. Epub 2008 Feb 27.

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkn089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2367734PMC
April 2008

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Proc Natl Acad Sci U S A 2008 Feb 28;105(6):2070-5. Epub 2008 Jan 28.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0709662105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538882PMC
February 2008

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.

Genes Chromosomes Cancer 2008 Mar;47(3):253-9

Cancer Biology Program, Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20527DOI Listing
March 2008

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

Cancer Biol Ther 2007 May 13;6(5):661-7. Epub 2007 Feb 13.

Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.5.4003DOI Listing
May 2007